Știri
Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review
Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing Authorization Application (MAA) with the Citește mai mult...
0 de comentarii